If more blood sugar control is needed, the label allows further steps of 2.5 mg, each after at least 4 weeks on the current dose, up to 15 mg a week for adults. The earliest the top dose can be reached is week 21.
The steps after 5 mg are optional, and the label ties each one to blood sugar. This page puts the schedule on your calendar and shows what 5, 10 and 15 mg did in the trials, how side effects change with the dose, and what the label says about a late or missed shot.
What is the Mounjaro dosing schedule, with my dates?
Enter the date of your first dose and pick the dose your prescriber is aiming for. The list shows the earliest date the label allows for each step.
Log each shot and the app keeps the dates for you.
Open the appThe numbers along the bottom of the chart are weeks of treatment. These are the earliest dates the label allows, not a plan: a dose is increased only if more blood sugar control is needed, and your prescriber decides each step.
| Weeks, at the fastest pace | Weekly dose mg | What the label says |
|---|---|---|
| 1 to 4 | 2.5 | Starting dose; not intended for blood sugar control |
| 5 to 8 | 5 | The first step, for everyone |
| 9 to 12 | 7.5 | If needed, after at least 4 weeks on 5 mg |
| 13 to 16 | 10 | If needed; the maximum for pediatric patients |
| 17 to 20 | 12.5 | If needed |
| 21 onward | 15 | If needed; the maximum for adults |
Mounjaro prescribing information, section 2.1.1
Why does Mounjaro start so low?
To reduce stomach and gut side effects. The label says the dose escalation is there for that reason, and that most reports of nausea, vomiting and diarrhea came during the dose increases and then decreased over time.1
The starting dose is not meant to work on blood sugar. The label calls 2.5 mg a dose for treatment initiation that is not intended for glycemic control.1 The first four weeks prepare the body for the doses that follow.
The level in the blood takes time to build as well. Tirzepatide has a half-life of about 5 days, so each weekly dose lands on what is left of the one before. In our model of the fastest schedule, the weekly peak reaches 16% of the settled 15 mg level by the end of the first month, 33% by the end of the second, 50% by the end of the third and 100% in week 24.
| Weeks | Dose mg | Weekly peak, as a share of settled 15 mg |
|---|---|---|
| 1 to 4 | 2.5 | 10% rising to 16% |
| 5 to 8 | 5 | 27% rising to 33% |
| 9 to 12 | 7.5 | 43% rising to 50% |
| 13 to 16 | 10 | 60% rising to 66% |
| 17 to 20 | 12.5 | 77% rising to 83% |
| 21 to 24 | 15 | 93% rising to 100% |
Our model: one compartment, half-life 5 days, peak 24 hours after the injection.
Does twice the dose mean twice the level?
Yes. The label says tirzepatide exposure rises in proportion to the dose, and that the level settles after 4 weeks of weekly injections. Eighty percent of an injected dose reaches the blood, and the highest level after a shot comes between 8 and 72 hours later.1
Four weeks is also the minimum length of each step, so by the time the next step is allowed the level from the current dose has settled. The results did not rise in the same proportion. Tripling the dose from 5 mg to 15 mg tripled the level and, in the 40-week trial, left HbA1c where it was and added 1.5 kg of weight loss.
Which dose do people stay on?
Any dose from 5 mg up. The label does not name a single maintenance dose for Mounjaro. It says to go to 5 mg after four weeks and to increase further only if additional blood sugar control is needed.1 A person whose blood sugar is controlled on 5 mg or 7.5 mg has no step left to take under that rule.
The maximum is 15 mg a week for adults and 10 mg for pediatric patients. The current label also covers pediatric patients aged 10 and older with type 2 diabetes, on the same starting dose and steps.1
Mounjaro has one approved use: to improve blood sugar control in type 2 diabetes, alongside diet and exercise.1 The same drug is sold as Zepbound for weight reduction, with its own label.
What did each dose do in the trials?
The trial of Mounjaro on its own, called SURPASS-1, ran for 40 weeks. It assigned 478 adults whose type 2 diabetes was not controlled by diet and exercise to placebo or to 5, 10 or 15 mg.1
Against placebo: 478 adults on diet and exercise alone, HbA1c about 8% and weight about 86 kg at the start. Against semaglutide: 1,879 adults already on metformin, HbA1c 8.3% and weight about 94 kg at the start.
For blood sugar, the three doses did the same. HbA1c fell 1.8 points on 5 mg and 1.7 points on 10 mg and on 15 mg, and about eight in ten people on any dose finished below 7%, against 23% on placebo.1
Weight was where the dose showed: 6.3 kg lost on 5 mg, 7.0 kg on 10 mg and 7.8 kg on 15 mg, against 1.0 kg on placebo. Going from the lowest to the highest maintenance dose added 1.5 kg over 40 weeks.1
Mounjaro alone, week 40
In this trial the average HbA1c result on 5 mg matched the result on 15 mg, and the label's side effect table, in the next section, shows fewer stomach and gut reactions on the lower dose.
How did each dose compare with semaglutide?
The label includes a direct comparison. SURPASS-2 gave 1,879 adults who were already taking metformin either Mounjaro 5, 10 or 15 mg or semaglutide 1 mg, the drug in Ozempic, for 40 weeks. Switch the chart above to that trial to see it.1
HbA1c fell 1.9 points on semaglutide and 2.0, 2.2 and 2.3 points on the three Mounjaro doses. The label reports the difference as statistically significant for 10 mg and 15 mg. Weight fell 5.7 kg on semaglutide and 7.6, 9.3 and 11.2 kg on Mounjaro.1
In this larger trial the dose mattered more for weight than in the trial of Mounjaro alone. The same holds across the other trials in the label.1
| Trial | 5 mg kg | 10 mg kg | 15 mg kg | Comparison group kg |
|---|---|---|---|---|
| 40 weeks, alone, against placebo | โ6.3 | โ7.0 | โ7.8 | โ1.0 |
| 40 weeks, with metformin, against semaglutide 1 mg | โ7.6 | โ9.3 | โ11.2 | โ5.7 |
| 52 weeks, against insulin degludec | โ7.0 | โ9.6 | โ11.3 | +1.9 |
| 52 weeks, against insulin glargine | โ6.4 | โ8.9 | โ10.6 | +1.7 |
| 40 weeks, added to basal insulin, against placebo | โ5.4 | โ7.5 | โ8.8 | +1.6 |
Mean change in body weight from the start of each trial. Mounjaro prescribing information, Tables 4 to 8.1
HbA1c moved less with the dose than weight did. In the trial against insulin glargine it fell 2.1, 2.3 and 2.4 points on 5, 10 and 15 mg; added to basal insulin it fell 2.1, 2.4 and 2.3 points.1
How many reached an HbA1c under 7%?
Across the five adult trials in the label, between 75% and 90% of people on any Mounjaro dose finished with HbA1c below 7%. Within a trial, the dose made a difference of at most 10 points.1
| Trial | 5 mg | 10 mg | 15 mg | Comparison group |
|---|---|---|---|---|
| Alone, against placebo | 82% | 85% | 78% | 23% |
| With metformin, against semaglutide 1 mg | 82% | 86% | 86% | 79% |
| Against insulin degludec | 79% | 82% | 83% | 58% |
| Against insulin glargine | 75% | 83% | 85% | 49% |
| Added to basal insulin, against placebo | 87% | 90% | 85% | 35% |
Share of patients with HbA1c below 7% at the end of each trial. Mounjaro prescribing information, Tables 4 to 8.1
Do side effects rise with the dose?
Yes. The label's table of common reactions comes from the placebo-controlled trials in adults.1
Placebo 235 people, 5 mg 237, 10 mg 240, 15 mg 241. Most reports of nausea, vomiting and diarrhea came during the dose increases and decreased over time.
Nausea was reported by 12% on 5 mg and 18% on 15 mg, against 4% on placebo. The share who stopped treatment because of stomach and gut reactions doubled between the lowest and the highest dose: 3.0% on 5 mg, 5.4% on 10 mg and 6.6% on 15 mg, against 0.4% on placebo.1
The label also lists four milder reactions that were more frequent on Mounjaro than on placebo. Belching was reported by 3.0% on 5 mg and 3.3% on 15 mg, against 0.4% on placebo; flatulence by 1.3% and 2.9%, against none; reflux by 1.7% on both doses, against 0.4%; and bloating by 0.4% and 0.8%, against 0.4%.1
Does the risk of low blood sugar rise with the dose?
Not on Mounjaro alone. In the 40-week trial without other diabetes medicines, no one on 5, 10 or 15 mg had a blood sugar below 54 mg/dL, against 1% on placebo, and no one had a severe episode.1
Added to basal insulin the picture changes, and it does not follow the dose in a straight line.1
| Added to basal insulin, 40 weeks | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| Blood sugar below 54 mg/dL | 13% | 16% | 19% | 14% |
| Severe episode, needing another person's help | 0% | 0% | 2% | 1% |
Mounjaro prescribing information, Table 2.1
What else changes besides the stomach?
The label reports several other changes from the placebo-controlled trials in adults.1
On Mounjaro, against placebo
On placebo the figures were a rise of 1 beat a minute, 0.4% for injection site reactions, 1.7% for hypersensitivity reactions and none for gallbladder disease. Heart rate is the one that follows the dose most clearly: episodes of fast heartbeat with a rise of 15 beats a minute or more were reported in 4.6% on 5 mg, 5.9% on 10 mg and 10% on 15 mg, against 4.3% on placebo.1
Pancreatic enzymes rose as well, amylase by 33% to 38% and lipase by 31% to 42% from the starting values.1
Do age, kidneys or liver change the dose?
No. The label recommends no dosage adjustment for kidney impairment, including end-stage kidney disease, and none for liver impairment; in both, the level of tirzepatide did not change.1
Thirty percent of the people on Mounjaro in the seven adult trials were 65 or older. The label found no overall differences in safety or effectiveness between them and younger patients, and adds that greater sensitivity in some older people cannot be ruled out.1
What if too much is injected?
The label says to consider contacting the Poison Help line at 1-800-222-1222 or a medical toxicologist, to treat the symptoms, and to allow for a period of observation because the half-life of tirzepatide is about 5 days.1 With six strengths, the strength printed on a new pen or vial is worth checking against the prescription before the first dose from it.
Which pen or vial holds which dose?
Every strength comes in every form.1
| Form | Doses inside |
|---|---|
| Single-dose pen | One |
| Single-dose vial | One |
| KwikPen, for one patient | Four weekly doses |
| Multi-dose vial | Four weekly doses |
Mounjaro prescribing information, section 3. Each form exists in 2.5, 5, 7.5, 10, 12.5 and 15 mg.1
The KwikPen is for one patient only: the label says never to share it, even if the needle is changed, because sharing can pass on blood-borne infections.1
A step up in dose means a new pen or vial of the next strength. The label asks prescribers to make sure the patient is trained on the form they receive, and again if the form changes.1
Storage differs by form. A single-dose pen or vial can be kept out of the refrigerator, at up to 86ยฐF (30ยฐC), for a total of 21 days. An opened KwikPen or multi-dose vial is thrown away after 30 days at room temperature, 30 days after first use, or after four weekly doses, even if medicine is left in it.1
What if I miss a dose?
Take it as soon as possible if no more than 4 days, 96 hours, have passed. After that, skip it and take the next dose on the usual day. In both cases the weekly schedule then continues as before.1
The curve is a model built on the label's half-life of about 5 days, for a settled dose. It is not a blood test.
On the day a dose is due, the level is at about 44% of the weekly peak in our model. Four days later, at the edge of the window, it is at 26%. The window is a day shorter than for Ozempic, whose drug leaves the body more slowly.
The label gives no rule for restarting after several missed doses. After a long gap, the dose to resume on is a question for the prescriber.
Can I change the day or the time?
Yes to both. Mounjaro is taken once a week at any time of day, with or without meals. The day can be changed if at least 3 days, 72 hours, separate the two doses.1
The injection goes under the skin of the abdomen or the thigh, or into the back of the upper arm when another person gives it, with a different site for each dose.1
What happens to my other medicines when the dose goes up?
The label attaches three instructions to the start and to every dose increase.1
Birth control pills. Mounjaro slows the emptying of the stomach, which can affect medicines taken by mouth. The label advises people who use oral hormonal contraceptives to switch to a non-oral method, or to add a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase. Hormonal contraceptives that are not taken by mouth should not be affected.
Insulin and sulfonylureas. Together with Mounjaro they raise the risk of low blood sugar, including severe low blood sugar, and the label says the risk may be lowered by reducing the dose of the sulfonylurea or the insulin.
Medicines that need a steady level. The label asks for monitoring of oral medicines that depend on a threshold concentration or have a narrow therapeutic index, and gives warfarin as the example.
What should be watched while the dose is rising?
Fluids and kidneys. Acute kidney injury has been reported, mostly in people who became dehydrated through nausea, vomiting or diarrhea. The label tells prescribers to monitor kidney function in people who report such reactions, especially at the start and during dose increases.1
Eyes. A rapid improvement in blood sugar has been linked to a temporary worsening of diabetic retinopathy, and the label says people with a history of retinopathy should be monitored for progression.1
What do the doses do in patients aged 10 and older?
The label's pediatric trial, SURPASS-PEDS, enrolled 99 patients aged 10 and older with type 2 diabetes that was not controlled on metformin, basal insulin or both. Their mean age was 15. They received 5 mg, 10 mg or placebo for 30 weeks.1
Pediatric trial, week 30
HbA1c of 6.5% or lower was reached by 68% on 5 mg and 81% on 10 mg, against 28% on placebo. BMI fell 6.9% on 5 mg and 10.8% on 10 mg, against 0.5% on placebo.1 The trial did not test doses above 10 mg, which is the label's maximum for this age group.
What does the label say about pregnancy and breastfeeding?
It says the data on Mounjaro in pregnant women are insufficient to judge the risk, that animal studies suggest there may be risks to the fetus, and that Mounjaro should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus. It also notes that poorly controlled diabetes in pregnancy carries risks of its own.1
For breastfeeding, a single-dose study found tirzepatide in breast milk to be undetectable or low compared with the mother's dose. The label adds that there are no data on effects on the breastfed infant or on milk production.1 The page on tirzepatide and birth control covers the contraception advice in detail.
How is this different from the Zepbound schedule?
The drug, the strengths and the pace are the same. The labels differ in what the dose is steered by.1,2
| Mounjaro | Zepbound | |
|---|---|---|
| Approved for | Blood sugar control in type 2 diabetes, from age 10 | Weight reduction and obstructive sleep apnea in adults |
| Start | 2.5 mg for 4 weeks, then 5 mg | 2.5 mg for 4 weeks, then 5 mg |
| Further steps | 2.5 mg at a time, if more blood sugar control is needed | 2.5 mg at a time, by response and tolerability |
| Maintenance | Not named; any dose from 5 mg | 5, 10 or 15 mg for weight; 10 or 15 mg for sleep apnea |
| Missed dose | Within 4 days | Within 4 days |
Current prescribing information for each product.1,2
The Zepbound dosing schedule has the calendar for weight management, and the page on the week between shots shows how the level of tirzepatide moves from one dose to the next.
Short answers to common questions
How long do I stay on 2.5 mg of Mounjaro?
Four weeks. The label then moves everyone to 5 mg once a week.
How long does it take to reach 15 mg?
At least 20 weeks: four weeks on each of 2.5, 5, 7.5, 10 and 12.5 mg. The first 15 mg dose is in week 21 at the earliest.
Do I have to go up to 15 mg?
No. The label allows an increase only if more blood sugar control is needed. In the 40-week trial, HbA1c fell about as much on 5 mg as on 15 mg.
Can I skip a step, for example from 5 mg to 10 mg?
The label describes increases of 2.5 mg at a time, each after at least 4 weeks on the current dose.
I missed my Mounjaro dose by three days. What now?
Take it as soon as possible: the label's window is 4 days. Then return to the usual day, keeping at least 3 days between doses.
Is the Mounjaro schedule the same as Zepbound's?
The doses and the four-week pace are the same. Mounjaro's steps are tied to blood sugar control, and Zepbound's label names 5, 10 and 15 mg as maintenance doses for weight.
Can children take Mounjaro?
The label covers patients aged 10 and older with type 2 diabetes, with a maximum of 10 mg a week.
Can I stay on 2.5 mg?
The label says 2.5 mg is for treatment initiation and is not intended for blood sugar control. After 4 weeks it moves to 5 mg.
Can I take Mounjaro together with insulin?
Yes. The combination raises the risk of low blood sugar, and the label says the risk may be lowered by reducing the dose of the insulin. In the trial where Mounjaro was added to basal insulin, 14% to 19% had a blood sugar below 54 mg/dL, against 13% on placebo.
Do I need a lower dose with kidney disease?
No. The label recommends no dosage adjustment for kidney impairment. It does ask for kidney function to be monitored in people who have stomach or gut reactions that could cause dehydration.
Does the injection site change how it works?
No. The label reports similar exposure to tirzepatide whether it is injected in the abdomen, the thigh or the upper arm. It asks for a different site with each dose.
How long does a dose stay in the body?
The half-life of tirzepatide is about 5 days, so half of a dose is cleared in that time. In our model, about 2% of the usual weekly peak is left four weeks after the last dose.
How the calendar works
The calendar adds 4, 8, 12, 16 and 20 weeks to the date of the first dose. Those are the earliest points at which the label allows 5, 7.5, 10, 12.5 and 15 mg. It does not know your blood sugar results, which is what the label ties each step to.
The bars show the label's published figures for the 40-week trial and for the pool of placebo-controlled trials in adults. The late-dose curve and the build-up table come from our level model: one compartment, a half-life of 5 days, a peak 24 hours after the injection.
Sources
- MOUNJARO (tirzepatide) injection prescribing information, NDA 215866/S-052, revised April 2026. U.S. Food and Drug Administration; sections 1, 2.1, 2.2, 3, 5.3, 5.5, 5.7, 6.1, 7.2, 14.2 and 16.2. accessdata.fda.gov
- ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026. U.S. Food and Drug Administration; sections 1, 2.1, 2.2 and 2.3. accessdata.fda.gov
Related analyses
Ozempic dosing schedule: 0.25 mg to 2 mg, week by week, with your own dates
Wegovy dosing schedule: the injection, the new 7.2 mg dose and the tablets, with your dates
Mounjaro side effects: how common each one is by dose, and when they ease
Mounjaro vs Zepbound: the same drug under two labels, compared by use, results and price
Log each dose and the app shows which week of the schedule you are in.
Open Dose Insider